Highlights d EM structure of TORC2 reveals a rhomboid shape with pseudo-2-fold symmetry 
In Brief
Rapamycin-sensitive TORC1 and rapamycin-insensitive TORC2 are multiprotein kinase complexes and key regulators of eukaryote physiology. Gaubitz et al. reveal the molecular architecture of TORC2 and why it is resistant to rapamycin, and generate a rapamycin-sensitive variant as a tool to dissect TORC2 signaling.
INTRODUCTION
Rapamycin is an antifungal, secondary metabolite produced by the soil bacterium Streptomyces hygroscopicus. The molecular basis underlying its toxic effect was defined genetically in Saccharomyces cerevisiae by the characterization of three mutations conferring resistance to rapamycin: fpr1, TOR1-1, and TOR2-1 (Heitman et al., 1991) . FPR1 encodes the proline isomerase FKBP12 (FK506 binding protein 12 kDa), which is an obligate receptor for rapamycin. Accordingly, fpr1 mutants confer recessive resistance to rapamycin. The FKBP12-rapamycin complex binds directly to the essential Targets of Rapamycin; atypical Ser/Thr-protein kinases encoded by TOR1 and its paralog TOR2. Missense mutations in the FKBP12-rapamycin binding domain (FRB) of TOR1 (Ser1972Arg, TOR1-1) or TOR2 (Ser1975Ile, TOR2-1) prevent FKBP12-rapamycin binding and thus confer dominant resistance to rapamycin (Cafferkey et al., 1993; Heitman et al., 1991; Helliwell et al., 1994; Kunz et al., 1993) . FKBP12 and TOR are conserved from yeast to man, but unlike yeast, higher eukaryotes possess a single TOR gene (mTOR in mammals).
Tor is the founding member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family (Keith and Schreiber, 1995) . PIKK members share a typical domain structure: their amino-terminal halves contain many repeated units of antiparallel a-helices clustering into two large domains: the HEAT (Hungtington, EF3A, ATM, TOR) and the FAT (Frap, ATM, and TRRAP) domains (Lempiä inen and Halazonetis, 2009) . Their carboxy-terminal portions contain the kinase domain, which, in TOR, includes the FRB domain and the FAT C-terminal (FATC) domain.
Biochemical purification of Tor1 and Tor2 proteins from yeast demonstrated that Tor functions in two distinct multiprotein complexes named TOR Complex 1 (TORC1) and TORC2 (Loewith et al., 2002) . Related complexes were subsequently identified in mammals (Hara et al., 2002; Jacinto et al., 2004; Kim et al., 2002; Loewith et al., 2002; Sarbassov et al., 2004) (Table 1) . TORC2 contains six subunits: Tor2, Lst8, Avo1, Avo2, Avo3, and Bit61 or its paralog Bit2 (Loewith et al., 2002; Wedaman et al., 2003) . All subunits are present in two copies per complex, yielding a mass of 1.4 MDa . In both yeast and mammals, FKBP12-rapamycin binds to Tor (Tor1, Tor2, or mTOR) in TORC1, but mysteriously not to Tor (Tor2 or mTOR) in TORC2 (Jacinto et al., 2004; Loewith et al., 2002; Sarbassov et al., 2004) . Consequently, only TORC1 activity is inhibited upon acute rapamycin treatment. This led to the hypothesis that the architecture of TORC2 or its unique composition might be responsible for the observed rapamycin resistance (Loewith et al., 2002) .
The use of rapamycin played a central role in pinpointing the functions of TORC1. The lack of a comparable TORC2-specific inhibitor has hindered its functional characterization. TORC2, via its main effector, the AGC family kinase Ypk1, regulates actin polarization, endocytosis, calcineurin activity, sphingolipid synthesis, and genome integrity, although the molecular mechanisms by which these distal effectors are regulated are not known (Roelants et al., 2011; Loewith and Hall, 2011; Niles et al., 2012; Shimada et al., 2013) .
In mammals, mTORC2 is activated downstream of growth factor signaling and by the ribosome (Laplante and Sabatini, 2012; Zinzalla et al., 2011) . The main effectors of mTORC2 are the AGC kinases Akt (PKB) and SGK. Akt is well known for its roles in glucose metabolism, apoptosis, proliferation, and migration (Brazil and Hemmings, 2001) . Consistently, aberrant mTORC2 signaling has been implicated in cancer progression (Sparks and Guertin, 2010) .
Despite their clinical importance, structural information on TOR complexes is scarce. A negative stain EM structure of yeast Tor1 and a Tor1-Kog1 complex (Adami et al., 2007) displayed a head and arm organization reminiscent of structures of other PIKK family members (Sibanda et al., 2010) . Subsequently, the cryo-EM structure of mTORC1 was determined at 26 Å resolution (Yip et al., 2010) . A 2-fold symmetry was observed, consistent with biochemical data suggesting that TOR complexes are dimeric . More recently, a 3.2 Å crystal structure of the mTOR FAT, FRB, kinase, and FATC domains (mTOR DNter ) in complex with mLst8 was reported . This study demonstrated that the kinase domain folds into a canonical bilobal structure, which is tightly wrapped by the FAT domain and suggested that the FRB domain acts as a gatekeeper by restricting access of substrates to an intrinsically active kinase pocket. With regard to the other TORC2 subunits, only the crystal structure of the Avo1 pleckstrin homolgy (PH) domain has been reported (Pan and Matsuura, 2012) .
In this study, we have determined the molecular architecture of TORC2 by combining single-particle EM, subunit localization, and chemical crosslinking-mass spectrometry (XL-MS). The EM structure reveals a rhomboid-shaped particle with pseudo-2-fold symmetry and a pronounced central cavity. Subunit localization and XL-MS data led us to hypothesize that Avo3 could mask the FRB domain of Tor2 in TORC2, thereby conferring insensitivity to inhibition by FKBP12-rapamycin. An unbiased genetic screen identified viable AVO3 alleles that fail to protect TORC2 activity from FKBP12-rapamycin, providing compelling experimental proof for our hypothesis and a novel tool to study TORC2 signaling in vivo. Visualization of FKBP12 bound to rapamycin-sensitive TORC2 localized the FRB domain within the TORC2 EM structure to a region near to that occupied by the C terminus of Avo3. Our TORC2 study thus reveals the basis for rapamycin insensitivity of this complex and suggests a molecular mechanism for TORC2 interaction with the plasma membrane and with substrates.
RESULTS
Negative Stain EM Structure of TORC2 TORC2 was purified from Saccharomyces cerevisiae cell extract to near homogeneity via protein A affinity purification of Avo3-TAP, as assessed by size exclusion chromatography (see Figure S1A online) . An initial 3D volume was calculated by random conical tilt (RCT) reconstruction using 8,762 tilt pair images of negatively stained specimens (Figures 1A and 1B; Movie S1) and refined against 24,979 untilted particles. The referencefree 2D class averages compare well with projections of the EM structure ( Figure 1C ). The data set shows preferential particle orientation, but all orientations are present ( Figure S1B ). The 3D reconstruction has a resolution of 26 Å according to the Fourier shell correlation 0.143 criterion (FSC after gold standard refinement, i.e., after independent refining of two halves of the data; Figure S1C ) (Rosenthal and Henderson, 2003) . Parallel refinement with Xmipp (de la Rosa-Trevín et al., 2013) and RELION (Scheres, 2012) resulted in virtually identical structures (CC = 0.97) ( Figure S1D ).
TORC2 is rhomboid shaped with dimensions of 320 Å 3 230 Å 3 220 Å and an estimated Voronoi volume of 2.1 3 10 6 Å 3 ( Figure 1B ). The complex delimits a central cavity with dimensions of 70 Å 3 114 Å . The structure displays a pseudo-2-fold symmetry along the z axis, and the two protomers have a correlation coefficient of 0.89. The protomer interface itself is small, with an area of only 14 3 10 3 Å 2 ( Figure 1B) . Notably, the structure of TORC2 shares three features with the mTORC1 structure (Yip et al., 2010) : a rhomboid shape, a (pseudo-) 2-fold symmetry where each subunit is present in two copies, and a central cavity delimited by the protomer interface ( Figures 1B,  1D , and S1E). However, the two complexes diverge markedly in their overall size, the surface area of the protomer interface, and the volume and shape of the central cavity.
Subunit Mapping in TORC2
Each protomer of TORC2 resembles a hand and was thus subdivided into a palm, a thumb, and four fingers ( Figure 1B) . We keep these designations throughout the manuscript when referring to specific regions of the EM map. To determine the position of individual subunits within TORC2, we performed negative stain EM analyses of TORC2 variants purified from strains either lacking a subunit or expressing a subunit fused to an antibody epitope tag, or a bulky MBP tag. Single particles were subjected to 2D multivariate statistical analysis (MSA) and classification (van Heel et al., 1996; de la Rosa-Trevín et al., 2013) . The resulting 2D class averages were compared to averages of TORC2 particles purified from AVO3-TAP cells (annotated as control preparations in Figure 2 ). We first localized the nonessential proteins Bit61/Bit2 and Avo2. Deletion of BIT61 and its paralog BIT2 yielded TORC2 particles lacking density at the tip of finger 2 (Figures 2A and S2A) . Consistently, TORC2 particles containing a Bit61-MBP fusion protein displayed extra density in proximity to finger 2 ( Figures  2A and S2A) . Deletion of AVO2 resulted in loss of density in finger 3 ( Figures 2B and S2B ). The peripheral localizations of Avo2 and Bit61/Bit2 in fingers 2 and 3, respectively, agree with the obser- Yip et al., 2010 ) is shown at the same scale. See also Figure S1 and Movie S1.
vation that these proteins are not essential for TORC2 assembly and function . Consistently, a 2D heterogeneity analysis with the double MSA method demonstrated that Bit61/2 can dissociate from TORC2 ( Figure S2A ). Avo1 and Avo3 are essential TORC2 subunits thought to serve as scaffolds in TORC2 assembly . We localized the C terminus of Avo1 by negative stain EM of TORC2 particles containing Avo1 fused to a myc-tag ( Figures 2C and S2C ). Upon addition of the a-myc antibody, extra density appeared proximal to the thumb in 2D class averages. The C terminus of Avo1 contains a PH domain, which is required to target TORC2 to the plasma membrane (Berchtold and Walther, 2009 ). 2D class averages of TORC2 particles containing a truncated form of Avo1 missing the PH domain lacked density within the thumb ( Figures 2C and S2C) . Thus, the C terminus and the PH domain of Avo1 are localized in the thumb next to the protomer interface of TORC2.
To determine the position of the C terminus of Avo3, we added an antibody recognizing the calmodulin-binding peptide moiety of the TAP tag to our standard TORC2 purifications. 2D class averages of the dorsal view of TORC2 indicate that the antibody recognizes an epitope localized within the palm, in proximity to finger 3, which contains Avo2 ( Figures 2B and S2D ). To localize the N terminus of Avo3, we purified TORC2 from cells expressing MBP-Avo3-TAP. In the 2D class averages of the dorsal view, extra density can be observed near the base of finger 1 ( Figure 2B) ; addition of an anti-MBP antibody indicated a location of the Avo3 in the center of the complex ( Figure S2D ). Together, these patterns suggest that Avo3 is located within the palm of the complex. This hypothesis is supported by XL-MS experiments indicating that Avo3 is ''U'' shaped and in close proximity to the Tor2 kinase domain, which we also localize to the palm (see below).
Purification of TORC2 DLst8 yielded intact particles ( Figure 2B ), but we could not detect a well-defined loss of density in negative stain EM 2D class averages. In a further attempt to localize Lst8, a negative stain 3D reconstruction of TORC2 DLst8 was generated ( Figure S2B ). Its overall structure was similar to TORC2, and again we could not observe loss of density which would correspond to a 34 kDa protein with a WD40 domain. Introducing tags to localize Lst8, the HEAT repeats in Tor2, the C terminus of Tor2, and the amino terminus of Avo1 proved to be detrimental to the integrity of TORC2 during the purification. In conclusion, we identified the localization of the subunits Avo1 (PH domain/C terminus), Avo2, Avo3 (N and C termini), and Bit2/61 (Figure 2 ) in the TORC2 reconstruction using negative stain EM. Figure 3A ; Table S3 and Table S4 ) .
To assess the quality of this data set, we first mapped intramolecular crosslinks in Tor2 onto a homology model of Tor2 1367-2474 (Tor2
DN
) based on the mTOR DN -mLst8 structure ) ( Figure S3A ). The average lengths of the corresponding crosslinks are 18.6 ± 5.3 Å ( Figure S3B ), which is well within the previously reported average crosslink distance of up to 30 Å for BS 3 and DSS (Merkley et al., 2014) and, as such, simultaneously validates both the Tor2 DN homology model and the XL-MS data. We identified seven intermolecular crosslinks between the central part of Avo1 and Lst8 ( Figures 3A and 3B ). The lysines crosslinked to Avo1 are found on blades 1, 3, and 6 of the WD40 domain of Lst8, on the propeller face opposite to the Tor2 interaction site described by Yang and coauthors . This suggests that Lst8 is sandwiched between the kinase domain of Tor2 and Avo1, an observation that is consistent with the recognized function of WD40 repeat proteins as rigid scaffolds mediating protein-protein interactions. It is noteworthy that even though Tor2 and Lst8 interact closely , no Tor2-Lst8 crosslinks were observed in our XL-MS data, likely due to the paucity of lysines at the interaction site. A detailed theoretical analysis of the potential crosslinks between Lst8 and Tor2 (Supplemental Experimental Procedures) shows that crosslinking and proteolytic digestion results in peptides inappropriate for MS analysis.
The XL-MS data also contained a rich collection of intramolecular crosslinks involving Avo3 and a complex pattern of crosslinks between Tor2 and Avo3. Avo3 displayed 28 intramolecular crosslinks, and their pattern suggests that Avo3 adopts a ''U'' shape ( Figure 3 ). Of the six intermolecular crosslinks between Avo3 and the Tor2 FAT domain, the FRB domain and the kinase domain ( Figures 3B and 3C Figure 3C ). A more refined localization of the N terminus of Avo3 was not possible, as no crosslinks involving the first 100 residues of Avo3 were recovered. This region of Avo3 is poorly conserved and predicted to be unstructured ( Figure S4 and data not shown) and may be rather distal from the C terminus of Avo3, as suggested by our negative stain EM data ( Figure 2 ). Finally, a C-terminal lysine of Avo3 is crosslinked to a C-terminal lysine of Avo2, consistent with the proximity of Avo2 and Avo3, as suggested by the antibody labeling experiments ( Figures 3A  and 2B ).
Deletion of a Carboxy-Terminal Portion of Avo3 Renders TORC2 Sensitive to Rapamycin Why does rapamycin-FKBP12 bind TORC1 but not TORC2? We previously hypothesized that a TORC2-specific subunit occludes the FRB domain of Tor2 and thereby prevents binding of the rapamycin-FKBP12 complex to TORC2 (Loewith et al., 2002) . Our XL-MS experiments and EM subunit localizations suggested that Avo2 and Avo3 are located close to each other and to the FRB domain of Tor2. We tested if either or both of these subunits confer rapamycin resistance to TORC2 by means of a yeast growth assay. First, we rendered TORC1 resistant to rapamycin by replacing TOR1 with the rapamycin-resistant TOR1-1 allele (K1972R; Cafferkey et al., 1993; Heitman et al., 1991; Helliwell et al., 1994) . Subsequent deletion of AVO2 in this background did not trigger sensitivity to rapamycin (data Table S3 and  Table S4 .
(B) Close-up of the intermolecular crosslinks mapped to the Tor2 DN :Lst8 model generated from the mTOR DN -Lst8 crystal structure . See also Figure not shown), demonstrating that Avo2 alone does not occlude the FRB domain of Tor2 in TORC2. Similar analyses of AVO3 were not possible, as the deletion of this gene is lethal and results in dissociation of TORC2 .
To circumvent this, we screened a library of AVO3 mutants with the aim to identify alleles that confer rapamycin sensitivity upon TORC2 ( Figure 4A ). Of approximately 15,000 avo3 plasmids that complemented the loss of endogenous AVO3, ten failed to support growth in the presence of rapamycin. Two of these clones supported wtgrowth rates in the absence of rapamycin. Sequencing of the plasmids rescued from these clones demonstrated identical missense mutations, which result in truncation of the last 157 amino acids of Avo3. This C-terminal truncation of Avo3 was introduced into the genomic AVO3 locus. Again, these cells presented no obvious growth defects when cultured in standard growth medium, but their growth was sensitive to low-nanomolar concentrations of rapamycin ( Figure 4B ). At growth-inhibitory concentrations of rapamycin, inhibition of TORC2
Avo3DCT was rapid, causing Ypk1 dephosphorylation within 5 min ( Figure 4C ). Importantly, inhibition of TORC2
Avo3DCT by rapamycin occurred at comparable concentrations and with comparable kinetics to those observed with TORC1 ( Figure 4C ). These genetic and biochemical experiments confirm our crosslinking data and demonstrate that the C-terminal region of Avo3 and the FRB domain of Tor2 are in close proximity within TORC2. Strikingly, deletion of the Avo3 C-terminal region is sufficient to render TORC2 rapamycin sensitive. Our experiments revealed the Avo3-Tor2 interaction as the molecular basis of rapamycin insensitivity of TORC2, answering a long-standing question in the TOR community.
AVO3 orthologs are found throughout the eukaryote kingdom ( Figure S4A ). We investigated whether it is possible to generate a C-terminally truncated mammalian Avo3 (Rictor) mutant that would similarly render mTORC2 sensitive to rapamycin. Based on the sequence alignment of Rictor with yeast Avo3 (A) Screening rationale to identify viable alleles of AVO3 that render TORC2 sensitive to rapamycin. TOR1-1 GAL1p-AVO3 cells, which are resistant to rapamycin but inviable on glucose-containing media, were transformed with a library of plasmids containing mutagenized AVO3 expressed from its own promoter. Functional, plasmid-borne AVO3 alleles were identified by their ability to restore growth on glucose-containing media. These transformants were subsequently replicated to rapamycin-containing glucose plates, and those that failed to grow were selected for further analysis. ( Figure S4B ), we generated a Rictor construct that expresses a protein lacking the C-terminal 635 amino acids. However, unlike full-length Rictor, these truncated versions of Rictor did not rescue Akt S473 phosphorylation after deletion of Rictor in Rictor f/f MEFs, demonstrating that these alleles are not functional in mTORC2 ( Figure S4C ). Complementation with smaller C-terminal truncations of Rictor (lacking 485 and 127 C-terminal amino acids) also failed to yield functional, rapamycin-sensitive mTORC2 (data not shown). The essential nature of the C terminus of Rictor thus precludes the straightforward generation of a rapamycin-sensitive mTORC2.
Rapamycin-Sensitive TORC2 Reveals TORC2 Function in Cell-Cycle Progression In Vivo We exploited our engineered sensitivity of TORC2 to rapamycin as a means to probe TORC2 function in vivo. Genetic inactivation of TORC2, using promoters that can be regulated or temperature-sensitive alleles of genes encoding TORC2 subunits, had previously shown that chronic inactivation of TORC2 leads to a depolarization of the actin cytoskeleton (Helliwell et al., 1994; Loewith et al., 2002) . Similarly, specific inactivation of TORC2 with rapamycin in AVO3 DCT TOR1-1 cells caused a pronounced depolarization of the actin cytoskeleton in less than 30 min of treatment ( Figure 4D ). Acute inhibition of TORC1 leads to cellcycle arrest in G 1 (Barbet et al., 1996) . Remarkably, in our experiments, rapamycin inhibition of TORC2 triggered a rapid cell-cycle arrest in G 2 /M ( Figure 4E ). This observation demonstrates that both TOR complexes have important but different roles in regulating cell-cycle transition checkpoints, and underscores the potential of our system as a highly useful tool to identify novel effectors downstream of TORC2.
TORC2 Architecture
As noted above, our initial efforts to localize Tor2 were hindered by our inability to recover intact TORC2 molecules from cells expressing tagged Tor2 kinase. We were particularly keen to localize the Tor2 kinase domain in TORC2 and rationalized that we might be able to exploit our rapamycin-sensitive TORC2 to achieve this goal by visualizing the binding of GST-FKBP12,rapamycin to TORC2 Avo3DCT particles. To this end, we first confirmed that the inhibition of TORC2 Avo3DCT in vivo required FPR1 (the gene that encodes the yeast FKBP12 ortholog) and an intact FRB domain in Tor2 ( Figures 5A and 5B ). Consistently, kinase activity of TORC2 Avo3DCT assessed in vitro was sensitive to the addition of FKBP12 + rapamycin, while the activity of intact TORC2 was not ( Figure 5C ). From these observations we conclude that the inhibition of TORC2
Avo3DCT by rapamycin requires both an intact FRB and FKBP12 and is thus mechanistically similar to the inhibition of TORC1 by FKBP12,rapamycin.
To observe the position of the Tor2 kinase domain, we exploited our rapamycin-sensitive TORC2
Avo3DCT for 2D EM analysis. New density in the 2D class averages was observed upon addition of GST-FKBP12 and rapamycin to TORC2 Avo3DCT preparations. This density is localized next to the thumb ( Figures 5D  and S5 ). As this additional density was not observed in the absence of rapamycin, we conclude that it corresponds to the GST-FKBP12 protein. From this, we infer that the FRB domain localizes to the density connecting finger 1 and the thumb. Integration of all negative stain EM and XL-MS localization data allows us to propose a model for TORC2 subunit organization ( Figure 6 ). EM characterization of TORC2
DAvo2

and TORC2
DBit61/DBit2 allowed unambiguous determination of the overall location of Avo2 and Bit2/61 to fingers 3 and 2, respectively (Figures 2, S2A, and S2B). Based on our EM localization ( Figures 2C and S2C ), we found that the C terminus of Avo1, including its PH domain, is located in the thumb. We localized the kinase domain, more specifically the FRB of Tor2, to the density connecting finger 1 and the thumb. Using the FRB domain as an anchor point, we placed the Tor2 DN -Lst8 model into the RCT volume. This placement localizes Lst8 to the base of finger 1, proximal to the thumb/Avo1. This positioning of Lst8 is thus consistent with the multiple crosslinks observed between the middle portion of Avo1 and Lst8 ( Figures 3A and 3B) . A sandwiched position of Lst8 with one side of its WD40 domain binding to Avo1 and the other to the Tor2 kinase domain is further supported by our observation that (1) Lst8 tagging interfered with TORC2 integrity (data not shown) and (2) Lst8 deletion does not lead to a loss of ring-shaped density as expected for a WD40 propeller motif (Figures 2B and S2B) .
In the resulting model ( Figure 6A ), the Tor2 kinase domain resides at the base of finger 1, with the FRB domain, ATP-binding site, and substrate loop of the kinase being accessible from the lateral and dorsal side proximal to Avo1. Avo3 was localized by EM in the dorsum. This positioning is corroborated by XL-MS data ( Figures 3A and 3C ) and our biochemical studies of rapamycin-sensitive TORC2 ( Figure 5 ). Avo3, which contains a large a-helical Armadillo repeat domain, extends throughout almost the entire length of the structure from close to the central cavity across to the opposite side close to Bit61/2 in our model (Figure 6 ). This placement of Avo3 is supported by crosslinks between Avo3 and Avo2 as well as between Avo3 and Bit61 ( Figure 3A ) and is consistent with a previously identified Bit61-Avo3 interaction in a yeast two-hybrid assay (Tarassov et al., 2008) .
DISCUSSION
TOR complexes serve as key regulators of metabolic homeostasis and are clinically important drug targets. However, structural insight into their function has been limited to date, partly due to difficulties with recombinant expression and inherent instability of the individual subunits. We overcame these challenges by characterizing endogenous TAP-purified yeast TORC2 and further interrogating the complex by chemical crosslinking-mass spectrometry. Our interdisciplinary approach sets the stage to better understand how this complex organizes into dimers and interacts with membranes, upstream regulators, and downstream substrates. The EM structure of TORC2 reveals a rhomboid pseudo-2-fold symmetric shape with a pronounced central cavity. A 2-fold symmetry is consistent with previous biochemical studies suggesting that TORC2 contains at least two copies of its six subunits , Jain et al., 2014 . These features are shared with mTORC1 (Yip et al., 2010) and may be generally important for Tor signal transduction. The role of the prominent central cavity in TORC2 remains enigmatic. Its dimensions (70 Å 3 114 Å ) would accommodate globular molecules with a molecular weight of up to 60 kDa. Given the position of the cavity in relation to the active site, macromolecules that bind to the complex from within this cavity would likely not be substrates. According to our model, portions of Avo3 and parts of the kinase domain could be accessible through this cavity (Figure 6 ). Noting that most other PIKKs are regulated upon binding of DNA/RNA, Yip and coauthors (Yip et al., 2010) speculated that the cavity in mTORC1 is a site for nucleic acid binding. However, to date, evidence supporting such interactions for either TORC1 or TORC2 is still lacking.
TORC2 Dimerization
The EM structure of TORC2 is distinct from the mTORC1 structure in several ways. With the length of the long axis approaching 35 nm, TORC2 is evidently larger than mTORC1. The protomerprotomer interface in mTORC1 involves large surfaces (Yip et al., 2010) , whereas the protomers of TORC2 are conjoined by rather small volumes between finger 4 and thumb ( Figures 1B and S1E ).
While we localized the C-terminal part of Avo1 to the thumb (Figure 2) , finger 4 remains unaccounted for. We speculate that the Tor2 HEAT repeats occupy this density. This tentative assignment, which is close to the protomer interface, is supported by previous reports implicating the HEAT domain of Tor in dimer formation (Zinzalla et al., 2010) . Thus, we suggest that the extended HEAT repeats of Tor2 and the N-terminal part of Avo1 localized in finger 4 and the thumb, respectively, conjoin the two protomers. This would be compatible with a recent single-particle pull-down study showing that mTOR alone is monomeric and that no single mTORC2 subunit serves as the dimerization component (Jain et al., 2014) . We note that dimerization of mTORC1 is reportedly responsive to metabolic status (Kim et al., 2013) as well as to the presence of rapamycin (Yip et al., 2010) . In contrast, we have never observed dissociated TORC2 protomer-like particles in EM images, supporting previous work suggesting that TORC2 dimerization is constitutive , Jain et al., 2014 . Moreover, in negative stain EM and 2D image analysis, we did not observe structural changes in TORC2 upon inhibition of the kinase with rapamycin ( Figure 5D ), nor an ATP-competitive inhibitor (10 mM NVP-BHS345) (data not shown).
Subunit Organization in the TORC2 Protomer and Implications for Substrate Recruitment
The PH domain of Avo1 ( Figure 2C ) recruits TORC2 to the plasma membrane (Berchtold and Walther, 2009 ). Our EM localization of the PH domain to the tip of the thumb ( Figure 2C ) indicates that it is the palm side of TORC2 that faces the plasma membrane. Our localization of the Tor2 kinase domain further implies that the ATP-and substrate-binding sites are accessible from the lateral-dorsal part of the structure next to the thumb comprising Avo1 ( Figure 5D , Figure 6 ). Previous work has suggested that Avo1 also plays a role in substrate recruitment (Liao and Chen, 2012; Liu et al., 2013; Lu et al., 2011) . Specifically, residues 600-840 of Avo1 were shown to bind to the central portion of Ypk2 (Liao and Chen, 2012) . This is the same region of Avo1 that displayed multiple crosslinks with Lst8 ( Figures 3A and 3B ). Lst8 in TORC2 is located close to the thumb and finger 1, sandwiched between Avo1 and the Tor2 kinase domain (Figure 6) . In contrast, mLst8 in mTORC1 protrudes from the core of the structure and is highly exposed (Yip et al., 2010) . This localization suggests that, beyond the kinase domain of mTOR, mLst8 does not interact with other mTORC1 subunits. In fact, Lst8 was shown to be essential for TORC2 function, but not for TORC1 function (Pracheil et al., 2012) . It is conceivable that loss of Lst8 would compromise Avo1 positioning and thus affect substrate recruitment and/or membrane localization. In agreement with this, loss of Lst8, like truncation of the PH domain, abolishes downstream signaling, but not TORC2 integrity (Figure 2 ).
These observations hint to an intimate link between the plasma membrane localization of TORC2, substrate recruitment, and Tor2 kinase activity. More specifically, our TORC2 architectural model suggests that substrates first approach the lateraldorsal face of TORC2 and are subsequently directed, via interactions with Avo1, to the active site, where they undergo phosphorylation. The peripheral subunits Avo2 and Bit2 were found to interact with the Slm1/2 proteins (Fadri et al., 2005; Uetz et al., 2000) . Slms localize to TORC2 domains in response to increased tension of the plasma membrane, where they may also play a role in the substrate recruitment process (Berchtold et al., 2012; Niles et al., 2012) . These structure-function implications are summarized in the cartoon in Figure 6B .
Rapamycin-Sensitive TORC2
Why Tor2 in TORC2 cannot be bound and inhibited by FKBP12-rapamycin has been a mystery in the TOR field for more than a decade. Here, we show that it is the C terminus of Avo3 that occludes the FRB of Tor2 in TORC2.
In their report of the mTOR DN -mLst8 crystal structure, Yang et al. (2013) suggest that the FRB domain restricts access to the catalytic pocket of mTOR. They also proposed that the FRB may serve as a specific substrate docking site. Thus, in their interpretation, binding of FKBP12-rapamycin to the FRB would compromise signaling both by occupying a substrate interaction site and by further restricting access to the active site. As it is masked by Avo3, the FRB of Tor2 in TORC2 is not readily accessible and therefore rather unlikely to be a substrate binding site. This suggests that restricted access to the active site alone is sufficient for FKBP12-rapamycin binding to inhibit TOR signaling. Curiously, in contrast to mTORC1, neither yeast TORC1 nor rapamycin-sensitive TORC2 is destabilized by the binding of FKBP12-rapamycin (Loewith et al., 2002 ; this study). The molecular basis for this difference is enigmatic.
Rapamycin has been widely used to characterize TORC1 function. In comparison, the lack of a pharmacological agent specific for TORC2 has made the study of this complex much more challenging. Our generation of a rapamycin-sensitive TORC2, based on our structural findings, now allows us to directly tackle this challenge. Specifically, in TOR1-1 avo3 DCT cells, TORC2 is acutely inhibited by rapamycin treatment, while TORC1 activity remains largely unaffected.
Genetic approaches, including the use of temperature-sensitive alleles and inducible gene promoters, have implicated TORC2 in the regulation of endocytosis, actin organization, the protein phosphatase calcineurin, and sphingolipid biosynthesis. The ability to acutely inhibit TORC2 through pharmacological intervention will greatly facilitate the molecular dissection of Membrane tension induces the association of Slm1/2 (SLM) proteins with the peripheral TORC2 subunits Bit61 and Bit2 (BIT) and Avo2 (Berchtold et al., 2012; Fadri et al., 2005) . SLM recruitment activates TORC2 signaling potentially by initially recruiting Ypk1/2 (YPK) to TORC2 (Niles et al., 2012) . Subsequently, a docking site in Avo1 (Liao and Chen, 2012) targets YPK into the catalytic pocket of Tor2. Lst8 interacts with the kinase domain and Avo1 and is possibly required for substrate recruitment by correctly positioning these domains. Avo3 plays a central scaffolding role. The Avo3 C terminus occludes the FRB domain of Tor2 rendering TORC2 insensitive to rapamycin. See text for further details.
these downstream signaling pathways and help identify novel TORC2-dependent pathways. Our rapamycin-based approach will serve as a useful complement to recently described chemical genetic approaches to inhibit TORC1 and TORC2 using yeastpenetrant imidazoquinolines that are ATP-competitive inhibitors of TOR (Kliegman et al., 2013; Shimada et al., 2013) . A better understanding of TORC2 functions will undoubtedly reinforce the emerging concept that mTORC2, like mTORC1, plays important roles in human health and disease (Cornu et al., 2013; Laplante and Sabatini, 2012) . Our rapamycin system allowed us to define a role for TORC2 in G 2 /M cell-cycle progression ( Figure 4E ). This function is likely to be conserved as mTORC2 and its substrate Akt (an AGC kinase orthologous to Ypk1) have previously been implicated in cellcycle regulation. Consistent with our finding that TORC2 has a role in G 2 /M progression, Akt was recently shown to be hyperactivated in G 2 (Liu et al., 2014b) . In this study, expression of phosphomimetic variants of Akt was found to suppress the cell-cycle defects of cyclin-deficient MEFs, thereby confirming that this potent oncoprotein contributes not only to survival signaling but also to cell-cycle progression (Liu et al., 2014b) . Akt is an appealing target for potential anticancer therapies; however, many Akt inhibitors have shown limited clinical efficacy due to general toxicity (Liu et al., 2014a) . Our discovery that TORC2 inhibition alone is sufficient to block the cell cycle suggests that mTORC2-specific inhibitors may provide new and potentially better therapeutic alternatives.
EXPERIMENTAL PROCEDURES
Sample Preparation TORC2 was prepared through pull-down of Avo3-TAP or Bit61-TAP from yeast extracts with IgG-coupled magnetic beads (Supplemental Experimental Procedures). This material was subsequently used for the preparation of EM grids and crosslinking. TORC2 particles with tags or deletions of different subunits were purified similarly (yeast strains are listed in Table S1 ). Size exclusion chromatography to assess homogeneity was performed using a Superose 6 PC 3.2/ 30 column connected to AKTA-Micro system (GE Healthcare Life Sciences).
Biochemical Assays
For in vitro kinase assays, TORC2 was purified via Bit61-TAP from cells expressing either Avo3
WT (CG1-34) or Avo3 DCT (MPr3). GST-ypk2-K373A (kinase dead; 500 ng /30 ml reaction) was purified from yeast, and recombinant GST-FKBP12 (800 ng/30 uL reaction) was produced in E. coli. Reactions were started by the addition of 300 mM ATP, 8.3 mM MgCl 2 , and 100 mCi [g-32P] ATP; incubated for 30 min in a thermomixer rotating at 800 rpm at 18 C; and terminated with the addition of 63 SDS-PAGE sample buffer. Samples were separated by SDS-PAGE, stained with Sypro ruby protein gel stain, and analyzed using a Bio-Rad molecular imager. In vivo activity of TORC1 and TORC2 was assayed by immunodetection of phosphoproteins in yeast extracts by quantitative western blotting using a LI-COR system. TCA extracts of yeast cultures treated with 200 nM rapamycin were prepared as described in Urban et al. (2007) .
Crosslinking and Mass Spectrometry TORC2 was crosslinked with the amine-reactive reagents BS 3 or DSS. The crosslinked complex was processed as described in the Supplemental Experimental Procedures, following the procedure of Leitner et al. (2014) . Mass spectrometry analysis was performed on a Thermo Orbitrap Elite instrument. Analysis of XL-MS data was performed using xQuest/xProphet .
Electron Microscopy
Negative stain EM was performed with samples stained with 2% uranyl acetate. Micrographs were collected using a JEOL 1200EX II, a FEI TECNAI G2 Sphera, or a Biotwin CM120 Philips (RCT data) microscope operated at 100 kV. The tilt pair (0 and 45 ) micrographs were corecorded at 26 kx magnification with a 4,000 3 4,000 TVIPS F415a CCD camera.
EM Data Processing
Single particles were manually selected using e2boxer (Ludtke, 2010) and tiltpicker ) (RCT pairs). 2D MSA and classification were performed with Imagic (van Heel et al., 1996) , and Xmipp (de la Rosa-Trevín et al., 2013 ). An ab initio 3D reconstruction of TORC2 was obtained by the Random Conical Tilt method using Xmipp .
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EXTENDED EXPERIMENTAL PROCEDURES Yeast strain generation
The TAP-tag was introduced according to Puig and collaborators (Puig et al., 2001 ). Deletion mutants have been constructed by replacing the respective ORF or peptide with a Kan marker cassette. Cterminal tags were introduced using PCR-based standard strategies (Longtine et al., 1998) . N-terminal tags were introduced using the pOM-vector cassettes (Gauss et al., 2005) . For the insertion of 8xHis-MBP tags, new insertion vectors using either pFA6a-or pOM-vectors as backbones have been designed (Supplementary Table S1 ).
TORC2 protein purification
Avo3-TAP or Bit61-TAP expressing strains were grown in Yeast Peptone Dextrose media (YPD) to an equivalent Optical Density at 600 nm of 5.0. Cells were pelleted, snap frozen in liquid Nitrogen and pulverized using Retsch MixerMill 400. The crude cell extract was prepared by resuspending the pellet in 1.5 volumes of extraction buffer (50 mM HEPES-KOH pH 7.5, 5 mM CHAPS, 300 mM KCl, 0,5 mM DTT, Phosphatase Inhibitor Mix, Complete Protease Inhibitor Cocktail (Roche; 1 tablet/ 50 ml) and 1 mM PMSF). After centrifugation, TORC2 was purified from the supernatant by ProteinA affinity purification using IgG-coated Dynabeads (M270 Epoxy, Invitrogen). Coated beads were added to the cell extract and incubated for 2 hours at 4°C with gentle continuous mixing. The supernatant was then removed, and the beads were washed five times with washing buffer (50 mM Hepes pH 7.5, 5 mM CHAPS, 300 mM KCl, 0.5 mM DTT). TORC2 was released by incubation with TEV protease for 1 hour at 18°C with constant gentle shaking. The supernatant was analyzed by SDS-PAGE (Supplementary Figure 1A) and by electron microscopy.
Mass spectrometric identification of proteins separated by SDS-PAGE
Bands were cut from the gel after silver staining, and in-gel digestion with trypsin was carried out using the procedure described by Shevchenko et al. (1996) . Elutes from the in-gel digestion procedure were analyzed by LC-MS/MS on a Thermo LTQ XL mass spectrometer (ThermoFisher Scientific) connected to an Easy nLC HPLC system (ThermoFisher Scientific). Ten percent of each digest were injected onto a 10 cm x 75 um column packed in-house with 3 um Magic C 18 beads (Michrom). HPLC separation was carried out at a flow rate of 300 nL/min using a gradient of 5-35% B over 40 min The mass spectrometer was configured for data-dependent acquisition with the following settings: MS and MS/MS spectra were acquired at normal scan speed. From each MS scan, the five most abundant precursors were selected for collision-induced dissociation at a normalized collision energy of 35%
and using an isolation window of 2.0 m/z. Previously selected precursors were put on an exclusion list for 30 s.
MS and MS/MS data were converted into the Mascot generic file format and searched using Mascot, version 2.4.01 (Perkins et al., Electrophoresis, 1999) against the yeast subset of the UniProt/SwissProt database (version 2013_06). Search settings were as follows: Enzyme = trypsin, with a maximum of two missed cleavages; fixed modification = carbamidomethylation on Cys; variable modification = oxidation on Met; mass tolerance = ± 1.5 Da for precursor ions and ± 0.6 Da for fragment ions; instrument type = ESI-TRAP. The maximum false discovery rate was set to 1%.
TORC2 gel filtration
TAP purified TORC2 was centrifuged at 16,000 g for 10 minutes with a table-top centrifuge (Eppendorf). A volume of 50 microliters of the supernatant was applied to a Superose 6 PC 3.2/30 preequilibrated with 50 mM Hepes pH 7.5, 5 mM CHAPS, 300 mM KCl, 0.5 mM DTT and connected to an AKTAmicro system (GE Healthcare). The chromatography was performed at flow rate of 0.05 ml/min.
Preparation of TORC2 for negative stain electron microscopy
A volume of 5 µl of purified TORC2 (~20 µg/ml) was applied onto thin continuous carbon support grids (EMS) and allowed to absorb for 1 min. The grid was washed two times with double-distilled water, and then stained with a drop of 2% uranyl acetate for 1 min. The stain was blotted off from the edge of the grid using filter paper and air-dried.
TORC2 subunit localization experiments
TORC2 was purified as described in the previous section. For immunolabeling, TORC2 particles containing C-terminally tagged Avo1-myc and Avo3-TAP were used. The anti-myc (Milllipore, clone 9E10), anti-TAP and anti-MBP antibodies (Open Biosystems CAB1001) were added to a final concentration of 2.5, 5, 10 or 25 μg/ml during the TEV cleavage step of the purification. Images were recorded under low dose conditions in a JEOL 1200E X II transmission electron microscope mounted with an Orios S600 camera or a FEI-Tecnai G2-F20 with a Pixis CCD camera. Particles were picked either automatically with Xmipp (de la Rosa-Trevín et al., 2013) or manually with e2boxer (Tang et al., 2007) . They were then subjected to reference-free alignment followed by classification based on hierarchical clustering with Xmipp 3 or multivariate statistical analysis with Imagic 5 (van Heel et al., 1996) . The 2D class averages were aligned, rotated and shifted with Imagic 5 for comparison with unlabelled TORC2. Eigenimages produced during the 2D MSA-run in Imagic 5 were closely inspected to access the confidence of the localizations. For assessment of the heterogeneity of the TORC2 sample (Supplementary Figure 2B ) the images were classified using the double-MSA approach described by Elad and collaborators (2008) .
Rapamycin-FKBP12 binding
GST-FKBP12 was purified from E. coli BL21 Star cells transformed with pGEX-6P-1; GST-FKBP12
and induced according to standard procedures. The cell pellet was resuspended in buffer (100 mM HEPES-KOH, pH 7.4, 300 mM KCl, 10% glycerol, 5 mM DTT, 5 mM PMSF, 5 mM amino-caproic acid, 2 mM leupeptin, 2 mM pepstatin, and Complete Protease Inhibitor Cocktail (Roche; 1 tablet/50 ml)) and cell lysis was performed using a French press. Unbroken cells and cell debris were removed by centrifugation (11,000 g, 15 min, 4 °C). GST-FKBP12 was purified using Glutathione Sepharose 4
Fast Flow affinity resin (GE Healthcare) followed by gel filtration with a Superdex75 10/300 column (GE Healthcare). GST-FKBP12 was obtained at a concentration of 160 μg/ml in 60 mM HEPES-KOH, and GST-FKBP12 (40 μg/ml final concentration) were added to TORC2
Avo3CT purified via Bit61-TAP.
TORC2, rapamycin/vehicle and GST-FKBP12 were incubated on ice for 30 min before being applied onto EM grids.
Random conical tilt (RCT) reconstruction
Micrographs were recorded at 0° and 45° tilt angles on a Biotwin CM120 Philips transmission electron microscope operating at 120 kV with a TVIPS F415a 4k × 4k CCD camera at a magnification 26,000×
(pixel size 4.5 Å). The contrast transfer function (CTF) was analyzed and corrected using bctf (Heymann and Belnap, 2007) . A total of 8,762 RCT pairs were picked manually with tiltpicker ) and additional untilted particles were picked with e2boxer.py amounting to a dataset of 24,979 particles (Ludtke, 2010) . The initial 3D reconstruction was calculated with the Xmipp ML tomo module from the tilted particles belonging to 133 classes of untilted particles generated with Xmipp . The 76 most representative volumes were averaged to compensate for the missing cone. The resulting map was refined against the 24,979 untilted particles until convergence with 3D maximum likelihood multi-reference refinement using Xmipp software (Scheres et al., 2009 ).
Negative stain reconstructions of TORC2
ΔAvo2
and TORC2
ΔLst8
For the 3D reconstructions of TORC2
ΔAvo2
and TORC2
ΔLst8
, micrographs were recorded and CTF corrected as described above. 6,810 particles of TORC2 were refined until convergence with the Xmipp mlf_refine3d module .
XL-MS of TORC2
TORC2 particles purified from 100 g of Avo3-TAP expressing cells were crosslinked by adding 0.6 mM BS Processing of the crosslinked samples followed a previously published procedure (Greber et al., 2014; Leitner et al., 2014) . Briefly, samples were resuspended in urea solution, disulfide bonds were reduced with tris(2-carboxyethyl)phosphine hydrochloride, followed by alkylation of free thiol groups using iodoacetamide. Reduced and alkylated proteins were digested with endoproteinase Lys-C (Wako) at 1:100 enzyme-to-substrate ratio (3 hours, 37 °C) and trypsin (1:50, overnight, 37 °C). The resulting peptide mixtures were purified by solid-phase extraction on SepPak tC18 cartridges (Waters) and eluted with 50% acetonitrile, 0.1% formic acid in water. The eluent was evaporated to dryness in a vacuum centrifuge and resuspended for peptide-level size exclusion chromatography (SEC) using a Superdex Peptide 3.2/30 column (GE Healthcare) as described previously . Three fractions (elution volume 1.0 -1.3 ml) were collected and evaporated to dryness.
LC-MS/MS analysis of the SEC fractions was carried out on an Orbitrap Elite mass spectrometer (ThermoFisher Scientific) connected to an Easy nLC 1000 HPLC system (ThermoFisher Scientific).
Approximately 1 ug of peptides per fraction (estimated from the UV signal of the SEC separation) was injected onto a PepMap RSLC column (15 cm x 75 um, 2 um particle size, ThermoFisher Scientific).
HPLC separation was performed at a flow rate of 300 nL/min using a gradient of 9-35% B over 90 min The mass spectrometer was configured for data-dependent acquisition with the following settings: MS spectra were acquired at a resolution of 120,000. The 10 most abundant precursors within the m/z range of 350-1,600 were selected for collision-induced dissociation in the linear ion trap at a normalized collision energy of 35% and using an isolation window of 2.0 m/z. Precursors with charge states of +1 and +2 were excluded from the selection, and previously selected precursors were put on a dynamic exclusion list for 30 s. MS/MS spectra were acquired in the linear ion trap at normal scan speed.
Orbitrap Elite MS and MS/MS data were converted into the mzXML format and searched using xQuest, version 2.1.1 ) against a database that contained sequences of the seven subunits of TORC2 obtained from UniProt and the 25 most abundant contaminants determined by direct LC-MS/MS analysis of the unfractionated sample. Only fully tryptic peptide sequences with a maximum of two missed cleavages were considered. Results were filtered according to a minimum peptide length of six residues, an interpreted total ion current of > 10% and a delta score of < 0.9. The estimated false discovery rate for the identified crosslinks (determined using xProphet ) was < 5% using a score threshold of 17.2.
Detailed analysis of potential crosslinked peptides between Lst8 and Tor2
A limitation of the chemical cross-linking methodology when applied to larger complexes such as TORC2 is that while overall many contacts may be observed, certain regions may be underrepresented.
This can be due to several reasons: Lack of lysine residues at or close to the binding interface, suboptimal sequence context so that the resulting peptides will be inappropriate for MS analysis upon proteolytic digestion, or unfavorable fragmentation properties of the cross-linked peptides that preclude their identification by database searching.
For instance, while Lst8 and Tor2 are in close proximity we could not identify cross-links in between them. We undertook a detailed analysis for this specific case. Using the homology model of the Lst8-Tor2 binary complex, we predicted theoretical cross-links between the two proteins using Xwalk (Kahraman et al., 2011; www.xwalk.org) . Assuming an upper Euclidean distance bound of 30 Å, only 14 Lys-Lys contacts were found to be spatially possible, of which only two were within 20 Å, and five span a distance of 25 Å, above which the likelihood that a cross-link is formed is already reduced. Next we looked at the sequence context of the lysine residues involved in these potential cross-links. Most of the peptides that would be produced after digestion with trypsin were exceeding a length of 20 residues, above which identification by tandem mass spectrometry becomes frequently suboptimal.
Several peptides, for example the one covering K180 of Lst8 (57 residues) were substantially longer, making them unidentifiable by MS/MS. Thus, of all the potential cross-links, only one did not contain a peptide exceeding 20 residues, but in this case the resulting peptide would only be six residues long. This is the lower acceptable limit that we chose for cross-link identification, and such short peptides frequently generate only few fragments, making them again difficult to identify. Therefore, it is not unrealistic that despite the close interaction between Lst8 and Tor2, no cross-links between these two proteins could be observed.
Mutagenesis of YCplac22::AVO3
10 μg of YCplac22::AVO3 plasmid (AVO3 expression driven from its own promoter/terminator) were mixed with 500 μl of hydroxylamine solution (1 M hydroxylamine dissolved in 0.45 M NaOH at a pH of 6.7) and incubated at 37 °C for 20 h. The DNA was purified with a PCR clean-up kit from Sigma before transformation.
Rapamycin-sensitive mutant screen
Mutagenized plasmids were transformed into RL370-4A. Approximately 15k primary transformants formed colonies on YPD (i.e. expressed an avo3 gene encoding a protein that could function in TORC2). These colonies replicated onto YPD containing 200 nM rapamycin and about 150 failed to grow in this medium. Upon restreaking, 10 of these demonstrated a reproducible sensitivity to rapamycin, 2 of which had otherwise wt growth and were selected for further analyses.
Characterization of TORC2
Avo3∆CT
For spot assays, cells were grown to mid-exponential phase in synthetic media diluted to an OD 600 of 0.15 and spotted in serial dilution (10 -1,-2,-3 ) with culture medium onto synthetic media plates with or 20 without rapamycin (200 nM). For growth assays, cells were pipetted into 96 well plates to an OD 600 of 0.075 in SD containing several dilutions of rapamycin. The plates were incubated at 30 °C without shaking and the OD 600 was monitored for 16 h.
To monitor the in vivo phosphorylation state of Sch9 and Ypk1 saturated cultures were diluted to an OD 600 of 0.2 and were grown to mid-exponential phase (OD 600 of 0.8). Cell growth was stopped by adding 100 % w/v TCA to a final concentration of 6 % v/v in order to preserve the phosphorylation status of the proteins. After harvesting, cell pellets were further processed for western blotting using a procedure as published previously (Urban et al., 2007) . A Licor Odyssey Scanner was used to detect phosphorylated Sch9 and Ypk1: Total Ypk1 was detected using antibody from Santa Cruz (yN-20)
1:1000 dilution. Phospho-T662 Ypk1, total Sch9, and phospho-T737 Sch9 were detected with rabbit polyclonal antisera ( (Berchtold et al., 2012) this study).
Construction and characterization of mTORC2 Rictor∆CT
In order to test in mammalian cells the AVO3 truncation that we identified in yeast, we used the pCI-HA-Rictor plasmid (pRL62-3) to introduce a stop codon corresponding to the amino acid position 1071 of mouse Rictor creating a 637 amino acids truncation. Tamoxifen-inducible Rictor knockout mouse embryonic fibroblasts (MEFs) were used to express the full length or truncated plasmids (Cybulski et al., 2012) . pCI-HA-Rictor and pCI-HA-Rictor Inhibitor Mix and Complete Protease Inhibitor Cocktail (Roche; 1.5 tablets/50 ml)), and cell lysis was performed using a Emulsiflex-C3. Unbroken cells and cell debris were removed by centrifugation (15,000 g, 15 min, 4 °C). GST-Ypk2 K373A was purified using Glutathione Sepharose 4 Fast Flow affinity resin (GE Healthcare) and subsequently dialysed over night at 4 °C against 50 mM HEPES-KOH pH 7.5, 5 mM CHAPS, 300 mM KCl, 0,5 mM DTT. was obtained at a concentration of 0.250 mg/ml.
GST-Ypk2
K373A and recombinant GST-FKBP12 (see above) were added to purified TORC2 along with 10 μM BHS, 100 nM rapamycin or vehicle controls as indicated in Figure 4 . The reactions were started by the addition of 300 μM ATP, 8.3 μM MgCl 2 and 100 μCi [g-32P] ATP, incubated 30 min at 18 °C in a thermomixer rotating at 800 rpm, and terminated with the addition of 6× SDS-PAGE sample buffer. Samples were separated by SDS-PAGE on a 9 % gel, stained with Sypro Ruby Protein gel stain and analyzed using a BioRad Molecular Imager.
Epifluorescence microscopy
Cells were grown in synthetic media at 30 °C to an OD 600 of 0.4. Rapamycin was added and cells were incubated for an additional 90 min. Cells were fixed by addition of 40 % formaldehyde and subsequently incubated for 30 min at room temperature with constant tumbling. After pelleting, cells were washed twice in 1x PBS and resuspended in 1x PBS containing 0.1 % Triton X-100. A subsequent 10 min incubation with the Triton buffer was followed by two washes with 1x PBS.
Rhodamine phalloidin was added and cells were incubated in the dark at 4 °C for 1 h. After two PBS washes, cells were resuspended in PBS with 60 % glycerol and imaged using a Zeiss Axio Z1 fluorescent microscope at 100 x magnification. Budding yeast cells were assessed for actin distribution as described previously by Helliwell et al. (Helliwell et al., 1998) . In brief, actin was considered as polarized if less than five patches were observed in the mother cell. Around 100 budding cells were counted per experiment; two biological replicates were performed for all experiments.
Fluorescence-Activated Cell Sorting analysis
DNA staining and flow cytometry were performed as previously described with slight modifications (Zhang and Siede, 2004) . Summarized, yeast cells were grown to an OD 600 of 0.3-0.4 in CSM synthetic media and treated with the desired drug for 3 h at 30 °C. For fixation, a 1.5 mL aliquot of the treated culture was collected and fixed with 70 % EtOH and incubated for some minutes. Cells were washed with water, collected and resuspended in RNase A solution (50 mM Tris pH 7.4, 200 ug/mL RNase A) and incubated for 2 h at 37 °C. Cells were spun down and resuspended in propidium iodide solution (50 mM Sodium citrate pH 7, 10 ug/mL propidium iodide) and incubated over night at 4 °C in
